{"id":"W4380084535","doi":"10.1002/hon.3163_109","title":"FAVEZELIMAB PLUS PEMBROLIZUMAB IN ANTI–PD‐1–REFRACTORY CLASSICAL HODGKIN LYMPHOMA (CHL): ESTIMATING THE RELATIVE EFFICACY OF FAVEZELIMAB","year":2023,"lang":"en","type":"article","venue":"Hematological Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"Jewish General Hospital","funders":"","keywords":"Pembrolizumab; Refractory (planetary science); Medicine; Internal medicine; Oncology; Clinical trial; Gastroenterology; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009289057,0.0005910596,0.001634462,0.0007297543,0.0001983818,0.0006443384,0.0006938864,0.0006038932,0.001357005],"category_scores_gemma":[0.008323478,0.0004383714,0.002398391,0.0005967037,0.0005118713,0.0009864644,0.0005914005,0.001038865,0.0002178936],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008692316,"about_ca_system_score_gemma":0.0004358767,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007299415,"about_ca_topic_score_gemma":0.0006644169,"domain_scores_codex":[0.9966052,0.002312387,0.0002908602,0.0003553991,0.0002997776,0.0001365322],"domain_scores_gemma":[0.9929409,0.005245848,0.0009696864,0.0003336444,0.0001816977,0.0003282233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7534528,0.002834237,0.1354061,0.001592371,0.01390561,0.0002172993,0.0003307324,0.01171239,0.01111418,0.0003381171,0.0004997397,0.06859647],"study_design_scores_gemma":[0.08973249,0.4296428,0.3925118,0.0003320536,0.030015,0.001317554,0.000501255,0.03643895,0.01146005,0.001533982,0.006389009,0.0001249658],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993102,0.004529299,0.0008985588,0.00005631197,0.00003291314,0.0004034998,0.0003480131,0.00001587687,0.000613539],"genre_scores_gemma":[0.9981089,0.0004544524,0.0007288561,0.00006137908,0.00004700751,0.0002507073,0.0002296056,0.000005328637,0.0001138637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009289057,"threshold_uncertainty_score":0.04912579,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04668407612535397,"score_gpt":0.349987444580797,"score_spread":0.303303368455443,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}